Drug Profile
Nesvategrast - OcuTerra Therapeutics
Alternative Names: OTT-166; SF-0166Latest Information Update: 19 Mar 2024
Price :
$50
*
At a glance
- Originator SciFluor Life Sciences
- Developer OcuTerra Therapeutics
- Class Eye disorder therapies; Imidazolidines; Naphthyridines; Propionic acids; Pyridines; Small molecules
- Mechanism of Action Integrin alphaVbeta3 antagonists; Integrin alphaVbeta6 inhibitors; Integrin alphavbeta8 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Diabetic retinopathy
- Phase I/II Diabetic macular oedema
- No development reported Wet age-related macular degeneration
Most Recent Events
- 14 Mar 2024 Efficacy and adverse event data from the phase II DR:EAM trial in Diabetic retinopathy released by OcuTerra Therapeutics
- 29 Dec 2023 OcuTerra Therapeutics completes a phase II DR:EAM trial in Diabetic retinopathy (Treatment-naive) in the US and Puerto Rico (NCT05409235)
- 18 Jul 2023 OcuTerra Therapeutics completes enrolment in its phase II DR:EAM trial for Diabetic retinopathy (Treatment-naive) in USA (Ophthalmic) (NCT05409235)